The Intravenous (IV) Ibuprofen Market to thrive owing to rising usage of pain management therapies

 

 Intravenous (IV) Ibuprofen Market 

The intravenous (IV) ibuprofen market involves the intravenous administration of ibuprofen, a medication used to relieve pain, fever, and inflammation. Ibuprofen belongs to non-steroidal anti-inflammatory drugs (NSAIDs) and works by blocking the production of prostaglandins, which are chemicals that promote pain. Growing demand for pain relief therapies among postoperative and cancer patients is boosting intravenous ibuprofen adoption. The key advantages of IV ibuprofen include rapid onset of action within 5 minutes of administration, longer duration of effect from 6 to 8 hours compared to oral ibuprofen, and greater bioavailability without first-pass metabolism in the liver.

The Global Intravenous (IV) Ibuprofen Market is estimated to be valued at US$ 11.13 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the intravenous (IV) ibuprofen market are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, Hikma Pharmaceuticals PLC. The companies are investing in R&D to develop new formulations, gain regulatory approvals, and expand to untapped markets.

Rising incidence of chronic diseases like cancer and musculoskeletal disorders along with increasing surgical procedures are fueling demand for pain relief therapies globally. This in turn drives the need for Intravenous (IV) Ibuprofen Market Size .

Technological advancements are focusing on developing alternate drug delivery systems for intravenous ibuprofen like pump infusion systems to enable cost-effective and precise drug administration in hospitals and home healthcare settings.

Market Trends

Continuous product pipeline expansion driven by R&D investments from leading pharma companies is a key trend observed in the intravenous ibuprofen market. Regulatory approvals for new formulations and regional expansions into emerging markets will support market growth.

Industry participants are also focusing on developing advanced drug delivery devices and kits to improve the ease of administration and expand the reach of intravenous ibuprofen in outpatient and ambulatory care settings.

Market Opportunities

Emerging markets like Asia Pacific and Latin America represent major opportunities for intravenous ibuprofen players due to growing medical needs and improving healthcare infrastructure in these regions.

Combination therapies leveraging the anti-inflammatory effects of intravenous ibuprofen along with other drugs can potentially drive new product developments catering to specific indications.

Impact of COVID-19 on Intravenous (IV) Ibuprofen Market Growth

The COVID-19 pandemic has significantly impacted the growth of the intravenous (IV) ibuprofen market. During the initial outbreak of the virus, major restrictions were imposed worldwide to curb the spread of the disease which hampered the manufacturing and supply chain operations. This led to shortages of intravenous ibuprofen supply in the markets. Hospitals faced issues in procuring the drug due to disrupted distribution channels. However, as ibuprofen is indicated for pain management in various surgeries and conditions, the demand rose significantly to treat COVID-19 patients with severe symptoms. Many clinical trials were also initiated to evaluate the effectiveness of intravenous ibuprofen in managing COVID-19 symptoms. This surge in demand and ongoing research activities helped the market to gradually recover in later parts of 2020. Going forward, approval of intravenous ibuprofen for COVID-19 treatment can boost the market growth. Companies are focusing on enhancing their production capacities and ensuring stable supply chains to cater to the increasing need for ibuprofen.

Geographical Regions with Highest Intravenous (IV) Ibuprofen Market Value

North America region holds the largest share of the intravenous (IV) ibuprofen market in terms of value. This is attributed to factors such as presence of major pharmaceutical players, higher healthcare spending, rising prevalence of various diseases requiring pain management and growing number of clinical research activities in the region. Within North America, the U.S. accounts for the maximum market share due to well-established healthcare infrastructure and reimbursement policies supporting drug development. Western European region occupies the second largest market position owing to increasing government and private investments in novel drug development. Emerging countries of Asia Pacific like China and India are expected to showcase fastest growth in the upcoming years due to growing medical tourism, rising healthcare standards and expanding base of generic pharmaceutical manufacturers.

Fastest Growing Region in Intravenous (IV) Ibuprofen Market

The Asia Pacific region is poised to experience the fastest growth in the intravenous (IV) ibuprofen market over the forecast period. This is majorly attributed to factors such as increasing healthcare expenditures, rapidly developing pharmaceutical industry, rising medical tourism, growing population offering larger patient base and rising per capita incomes in emerging Asian countries like China and India. Presence of leading contract manufacturing hubs and strengthening intellectual property laws supporting drug innovation will further support market expansion in Asia Pacific. Various initiatives taken by governments to improve healthcare infrastructure and availability of low-cost generics are expected toboost overall market growth. Growing geriatric population suffering from pain-causing conditions will also drive the demand for intravenous ibuprofen formulations across Asia Pacific markets.